StockNews.AISignal intelligence
Telomir Pharmaceuticals, Inc. Common Stock · NASDAQ · Healthcare
Browse public TELO signals with their source context and measured market impact. Open any signal for its permanent analysis page.
TELO shares surged by 20.3% on significant trading volume. Telomir-1 shows promise in reducing TNBC cell viability in lab studies. Telomir plans further studies on additional cancer types for drug development. Stock price is approaching its 52-week low of $1.12.
View signal analysisTelomir-1 shows effectiveness in reversing Type 2 diabetes parameters. Significant reductions in fasting plasma glucose levels were observed. Telomir-1 demonstrates age-reversal effects; improves lifespan and mobility. Ongoing research on Telomir-1 includes Alzheimer's and cancer applications.
View signal analysis